JP2022510962A5 - - Google Patents
Info
- Publication number
- JP2022510962A5 JP2022510962A5 JP2021531115A JP2021531115A JP2022510962A5 JP 2022510962 A5 JP2022510962 A5 JP 2022510962A5 JP 2021531115 A JP2021531115 A JP 2021531115A JP 2021531115 A JP2021531115 A JP 2021531115A JP 2022510962 A5 JP2022510962 A5 JP 2022510962A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- crenolanib
- pharmaceutical composition
- composition according
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779128P | 2018-12-13 | 2018-12-13 | |
| US62/779,128 | 2018-12-13 | ||
| US201962861424P | 2019-06-14 | 2019-06-14 | |
| US62/861,424 | 2019-06-14 | ||
| US16/713,935 | 2019-12-13 | ||
| US16/713,935 US11602533B2 (en) | 2018-12-13 | 2019-12-13 | Crenolanib combination therapy |
| PCT/US2019/066308 WO2020123991A1 (en) | 2018-12-13 | 2019-12-13 | Crenolanib combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022510962A JP2022510962A (ja) | 2022-01-28 |
| JP2022510962A5 true JP2022510962A5 (https=) | 2022-12-20 |
Family
ID=69596002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531115A Pending JP2022510962A (ja) | 2018-12-13 | 2019-12-13 | クレノラニブ併用療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11602533B2 (https=) |
| EP (1) | EP3893874A4 (https=) |
| JP (1) | JP2022510962A (https=) |
| CN (1) | CN110840893A (https=) |
| WO (1) | WO2020123991A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110840893A (zh) * | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
| CN113491693B (zh) * | 2020-03-19 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 法米替尼或其可药用盐在制备治疗Ras突变疾病的药物中的用途 |
| CA3186319A1 (en) * | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US20220047574A1 (en) * | 2020-08-15 | 2022-02-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pdgfr alpha mutated proliferative disorders |
| US20220079934A1 (en) * | 2020-09-17 | 2022-03-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pain |
| CN118576611A (zh) * | 2020-10-23 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 一种药物组合产品在制备用于治疗尤文氏肉瘤的药物中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| EP1641780B1 (en) | 2003-06-24 | 2008-11-12 | Pfizer Products Incorporated | Processes for the preparation of 1- [(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives |
| US20130230511A1 (en) * | 2012-02-03 | 2013-09-05 | Board Of Regents, The University Of Texas System | Biomarkers for response to tyrosine kinase pathway inhibitors in cancer |
| KR101738063B1 (ko) * | 2012-09-21 | 2017-05-19 | 아로그 파마슈티칼스, 인코퍼레이티드 | 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법 |
| EA039595B1 (ru) | 2012-10-05 | 2022-02-15 | Кадмон Корпорейшн, Ллк | Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела |
| MX373894B (es) | 2012-11-08 | 2020-07-09 | Clearside Biomedical Inc | Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| EP3060654B1 (en) | 2013-10-21 | 2023-03-15 | Hemoshear, LLC | In vitro model for a tumor microenvironment |
| US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| EP3120851A1 (en) * | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| CN110840893A (zh) * | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
-
2019
- 2019-09-26 CN CN201910917756.5A patent/CN110840893A/zh active Pending
- 2019-12-13 EP EP19896570.9A patent/EP3893874A4/en not_active Withdrawn
- 2019-12-13 US US16/713,935 patent/US11602533B2/en active Active
- 2019-12-13 JP JP2021531115A patent/JP2022510962A/ja active Pending
- 2019-12-13 WO PCT/US2019/066308 patent/WO2020123991A1/en not_active Ceased
-
2023
- 2023-02-09 US US18/166,636 patent/US20230181565A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022510962A5 (https=) | ||
| Ellis et al. | Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non–small cell lung cancer patients | |
| US20230181565A1 (en) | Crenolanib combination therapy | |
| EP3524268A1 (en) | Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers | |
| JP2020514311A5 (https=) | ||
| JP2019038796A5 (https=) | ||
| CN104436194A (zh) | 具有协同增效作用的抗癌组合物 | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| WO2010086964A1 (ja) | がん治療のための併用療法 | |
| CN105120663A (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| JP2008514577A5 (https=) | ||
| JP2019536783A5 (https=) | ||
| CN112236147A (zh) | 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法 | |
| Kamura et al. | Chemotherapy for advanced or recurrent cervical cancer | |
| KR102896612B1 (ko) | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 | |
| CN112121048A (zh) | 用于联合治疗食管癌的喹啉类化合物 | |
| TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| WO2021018310A1 (zh) | 用于治疗非小细胞肺癌的氨基吡啶衍生物 | |
| JP2023510853A5 (https=) | ||
| JP2016539149A5 (https=) | ||
| Mizushima et al. | A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer | |
| CN116672345A (zh) | Parp抑制剂和细胞毒性剂的联合产品及其用途 | |
| KR102265488B1 (ko) | 암 화학 요법시의 부작용 경감제 | |
| Geoffroy et al. | Chemotherapy of advanced gastrointestinal cancer | |
| Zhuanhong et al. | Effects of Tspan8 Gene Knockout Combined with Anlotinib on Proliferation, Migration, Invasion and Apoptosis of Colon Cancer SW480 Cells |